High-fat diet increases the level of circulating Monocyte Chemoattractant Protein-1 in Wistar rats, independent of obesity.
Diet-induced obesity
Experimental animal models
High-fat diet
Monocyte chemoattractant Protein-1
Wistar rat
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
10
02
2021
revised:
24
03
2021
accepted:
24
03
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
Low-grade chronic inflammation has emerged as a key pathogenic link between high-fat diet (HFD)-induced obesity and the increased risk of chronic diseases. Evidence has shown that HFDs may induce inflammation in the central nervous system and peripheral tissues. Monocyte Chemoattractant Protein-1 (MCP-1) is a product of various cells that is known to be an inflammatory marker. This study investigated whether a HFD could induce obesity and increase the level of MCP-1 in Wistar rats. The Wistar rats were randomized into two groups: normal diet (ND) and HFD (n = 12 per group). Both groups were fed for 8 and 16 weeks, thus dividing the rats into 4 arms: ND8, ND16, HFD8, and HFD16 (n = 6 per sub-group). Obesity in rats was measured using the Lee index. Blood samples were taken to measure the level of MCP-1. Our results showed that obesity did not occur in the group with a normal diet (ND8 and ND16). However, in the HFD group (HFD8 and HFD16), 4 of the 6 rats became obese. However, MCP-1 was significantly higher among non-obese rats in the HFD group compared with the ND group (p < 0.001). HFDs have been shown to increase the risk of obesity. In addition, increases in circulating MCP-1 were significantly different between Wistar rats given a HFD compared with the ND group.
Identifiants
pubmed: 33868686
doi: 10.1016/j.amsu.2021.102266
pii: S2049-0801(21)00216-8
pmc: PMC8047162
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102266Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interests.
Références
ISRN Endocrinol. 2012;2012:536905
pubmed: 22474595
Gut. 2019 Aug;68(8):1417-1429
pubmed: 30782617
Metabolism. 2019 Mar;92:6-10
pubmed: 30253139
Obesity (Silver Spring). 2013 Aug;21(8):1596-601
pubmed: 23666719
Physiol Behav. 1980 Aug;25(2):313-5
pubmed: 7413839
Arq Bras Cir Dig. 2013;26 Suppl 1:17-21
pubmed: 24463893
Nutrients. 2020 May 03;12(5):
pubmed: 32375231
Gut Microbes. 2012 Jul-Aug;3(4):279-88
pubmed: 22572877
Ann Med Surg (Lond). 2020 Dec 08;60:737-742
pubmed: 33425344
Am J Physiol Gastrointest Liver Physiol. 2020 Nov 1;319(5):G589-G608
pubmed: 32902315
Curr Obes Rep. 2018 Dec;7(4):276-288
pubmed: 30155850
Pharmacoeconomics. 2015 Jul;33(7):673-89
pubmed: 25471927
Ann Med Surg (Lond). 2020 Jul 22;57:118-122
pubmed: 32760580
Ann Nutr Metab. 2015;66 Suppl 2:7-12
pubmed: 26045323
Dis Model Mech. 2012 Sep;5(5):686-90
pubmed: 22381575
Int J Obes (Lond). 2017 Jan;41(1):149-158
pubmed: 27773938
J Neuroinflammation. 2016 Aug 26;13(1):206
pubmed: 27566530
Postgrad Med. 2009 Nov;121(6):21-33
pubmed: 19940414
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Front Immunol. 2018 Nov 13;9:2649
pubmed: 30483273
J Am Soc Nephrol. 2011 Oct;22(10):1846-55
pubmed: 21921143
Endocrinol Metab Clin North Am. 2008 Sep;37(3):635-46, viii-ix
pubmed: 18775356
Am J Physiol Gastrointest Liver Physiol. 2010 Aug;299(2):G440-8
pubmed: 20508158
J Lipid Res. 2013 Jan;54(1):152-63
pubmed: 23103474
Nutrients. 2020 Apr 14;12(4):
pubmed: 32295104
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
J Clin Invest. 2006 Jun;116(6):1494-505
pubmed: 16691291
Nutr Rev. 2008 Dec;66(12):684-94
pubmed: 19019037
Front Endocrinol (Lausanne). 2017 Mar 29;8:49
pubmed: 28424660
Curr Osteoporos Rep. 2019 Dec;17(6):538-547
pubmed: 31713180